CN112351778B - 稠合三环杂环类化合物及其治疗用途 - Google Patents
稠合三环杂环类化合物及其治疗用途 Download PDFInfo
- Publication number
- CN112351778B CN112351778B CN201980043105.6A CN201980043105A CN112351778B CN 112351778 B CN112351778 B CN 112351778B CN 201980043105 A CN201980043105 A CN 201980043105A CN 112351778 B CN112351778 B CN 112351778B
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691208P | 2018-06-28 | 2018-06-28 | |
| US62/691,208 | 2018-06-28 | ||
| PCT/US2019/039860 WO2020006432A1 (en) | 2018-06-28 | 2019-06-28 | Fused tricyclic heterocycle compounds and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112351778A CN112351778A (zh) | 2021-02-09 |
| CN112351778B true CN112351778B (zh) | 2023-04-04 |
Family
ID=68987618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980043105.6A Active CN112351778B (zh) | 2018-06-28 | 2019-06-28 | 稠合三环杂环类化合物及其治疗用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11535633B2 (enExample) |
| EP (1) | EP3813827A4 (enExample) |
| JP (1) | JP2021530442A (enExample) |
| KR (1) | KR20210025016A (enExample) |
| CN (1) | CN112351778B (enExample) |
| TW (1) | TW202019408A (enExample) |
| WO (1) | WO2020006432A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2929415T3 (es) | 2018-05-25 | 2022-11-29 | Incyte Corp | Compuestos heterocíclicos tricíclicos como activadores de STING |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| CN112552314B (zh) * | 2018-08-24 | 2022-03-04 | 杭州阿诺生物医药科技有限公司 | Sting激动剂小分子抗肿瘤化合物及其应用 |
| CN111655682B (zh) * | 2018-08-29 | 2024-05-31 | 杭州阿诺生物医药科技有限公司 | 一种高活性sting蛋白激动剂化合物 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020124059A1 (en) * | 2018-12-14 | 2020-06-18 | Eternity Bioscience Inc. | Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof |
| US12129267B2 (en) | 2019-01-07 | 2024-10-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US11155567B2 (en) | 2019-08-02 | 2021-10-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
| MY210304A (en) | 2020-04-02 | 2025-09-10 | Mersana Therapeutics Inc | Antibody drug conjugates comprising sting agonists |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| CN115554303B (zh) * | 2021-09-18 | 2024-07-09 | 上海科技大学 | 一种三环类化合物、其制备方法及其应用 |
| US20250171461A1 (en) * | 2022-02-21 | 2025-05-29 | Geode Therapeutics Inc. | Stimulator of interferon genes (sting) modulators, and compositions and methods thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2731708B1 (fr) * | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
| FR2747678B1 (fr) * | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| CA2324090A1 (en) | 1999-10-25 | 2001-04-25 | Leviton Manufacturing Co., Inc. | Electrical wiring device with multiple types of wire terminations |
| JP2009503069A (ja) | 2005-08-05 | 2009-01-29 | アストラゼネカ アクチボラグ | 三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用 |
| US20110262485A1 (en) | 2008-08-04 | 2011-10-27 | University Of Miami | Sting (stimulator of interferon genes), a regulator of innate immune responses |
| CA2825028A1 (en) * | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| CN104540945A (zh) | 2012-04-30 | 2015-04-22 | 格伦·N·巴伯 | 调节免疫应答 |
| US9527864B2 (en) * | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| CN109563081A (zh) | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
-
2019
- 2019-06-28 US US17/255,712 patent/US11535633B2/en active Active
- 2019-06-28 CN CN201980043105.6A patent/CN112351778B/zh active Active
- 2019-06-28 WO PCT/US2019/039860 patent/WO2020006432A1/en not_active Ceased
- 2019-06-28 TW TW108123007A patent/TW202019408A/zh unknown
- 2019-06-28 EP EP19825637.2A patent/EP3813827A4/en not_active Withdrawn
- 2019-06-28 JP JP2020570791A patent/JP2021530442A/ja active Pending
- 2019-06-28 KR KR1020207037227A patent/KR20210025016A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20210300944A1 (en) | 2021-09-30 |
| CN112351778A (zh) | 2021-02-09 |
| US11535633B2 (en) | 2022-12-27 |
| JP2021530442A (ja) | 2021-11-11 |
| EP3813827A4 (en) | 2022-04-13 |
| EP3813827A1 (en) | 2021-05-05 |
| TW202019408A (zh) | 2020-06-01 |
| KR20210025016A (ko) | 2021-03-08 |
| WO2020006432A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112351778B (zh) | 稠合三环杂环类化合物及其治疗用途 | |
| JP4866722B2 (ja) | 縮合ｎ−ヘテロサイクリック化合物およびｃｒｆ受容体アンタゴニストとしてのその使用 | |
| CN113637005A (zh) | 用于癌症治疗的kras抑制剂 | |
| CN111094289B (zh) | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2016501203A (ja) | インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物 | |
| WO2023274251A1 (zh) | 一类抑制rna解旋酶dhx33的多环化合物及其应用 | |
| IL301225A (en) | Heterocyclic compounds as CBP/EP300 bromodomain inhibitors | |
| JP2006515334A (ja) | ＣＲＦ受容体アンタゴニストとしてのヘテロアリール置換ピロロ［２，３−ｂ］ピリジン誘導体 | |
| CN110494431B (zh) | 氮杂环类衍生物、其制备方法及其医药用途 | |
| TW202007687A (zh) | 經進一步取代之三唑并喹噁啉衍生物 | |
| JP2023520595A (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| WO2023179567A1 (zh) | 作为Toll样受体激动剂的嘧啶并哒嗪酮类化合物 | |
| WO2014157687A1 (ja) | アセトアミド基を有する１，２，４－トリアジン－６－カルボキサミド誘導体 | |
| CN113195473B (zh) | 三环化合物作为sting激动剂及其制备方法和医药用途 | |
| CN115362155B (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
| WO2022111636A1 (zh) | 稠合三环化合物、其制备方法及其在医药上的应用 | |
| WO2018171611A1 (zh) | 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用 | |
| CN112574212B (zh) | 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| WO2013189241A1 (zh) | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 | |
| JP7729632B2 (ja) | 新規三環芳香族複素環化合物、ならびにその調製方法、医薬組成物および適用 | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| HK40045549A (en) | Fused tricyclic heterocycle compounds and therapeutic uses thereof | |
| CN109232533A (zh) | 氮杂环类衍生物、其制备方法及其医药用途 | |
| HUP0400460A2 (hu) | Kortikotropin-feloldó faktor (CRF) receptor antagonista triciklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
| CN109694351B (zh) | 苯并氮杂*衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40045549 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |